MX2024007749A - Formulaciones clinicas de anticuerpos anti-tigit. - Google Patents
Formulaciones clinicas de anticuerpos anti-tigit.Info
- Publication number
- MX2024007749A MX2024007749A MX2024007749A MX2024007749A MX2024007749A MX 2024007749 A MX2024007749 A MX 2024007749A MX 2024007749 A MX2024007749 A MX 2024007749A MX 2024007749 A MX2024007749 A MX 2024007749A MX 2024007749 A MX2024007749 A MX 2024007749A
- Authority
- MX
- Mexico
- Prior art keywords
- manufacture
- monoclonal antibodies
- pharmaceutical formulations
- tigit
- articles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292863P | 2021-12-22 | 2021-12-22 | |
| US202263383451P | 2022-11-11 | 2022-11-11 | |
| US202263387229P | 2022-12-13 | 2022-12-13 | |
| PCT/US2022/082139 WO2023122665A1 (en) | 2021-12-22 | 2022-12-21 | Clinical formulations of anti-tigit antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007749A true MX2024007749A (es) | 2024-07-01 |
Family
ID=85199491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007749A MX2024007749A (es) | 2021-12-22 | 2022-12-21 | Formulaciones clinicas de anticuerpos anti-tigit. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240408009A1 (https=) |
| EP (1) | EP4452320A1 (https=) |
| JP (1) | JP2025500483A (https=) |
| KR (1) | KR20240121771A (https=) |
| AU (1) | AU2022417501A1 (https=) |
| CA (1) | CA3242136A1 (https=) |
| IL (1) | IL313658A (https=) |
| MX (1) | MX2024007749A (https=) |
| TW (1) | TW202330034A (https=) |
| WO (1) | WO2023122665A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202515614A (zh) | 2023-08-25 | 2025-04-16 | 美商建南德克公司 | 治療非小細胞肺癌之方法及組成物 |
| WO2025174933A1 (en) | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| KR20220113414A (ko) | 2019-12-09 | 2022-08-12 | 제넨테크, 인크. | 항-pd-l1 항체 제제 |
| CN115052622B (zh) * | 2020-01-21 | 2026-03-06 | 夏尔巴生物技术(杭州)有限公司 | 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途 |
| TW202142230A (zh) * | 2020-01-27 | 2021-11-16 | 美商建南德克公司 | 用於以抗ｔｉｇｉｔ拮抗體抗體治療癌症之方法 |
-
2022
- 2022-12-21 AU AU2022417501A patent/AU2022417501A1/en active Pending
- 2022-12-21 CA CA3242136A patent/CA3242136A1/en active Pending
- 2022-12-21 JP JP2024538263A patent/JP2025500483A/ja active Pending
- 2022-12-21 EP EP22854694.1A patent/EP4452320A1/en active Pending
- 2022-12-21 IL IL313658A patent/IL313658A/en unknown
- 2022-12-21 MX MX2024007749A patent/MX2024007749A/es unknown
- 2022-12-21 WO PCT/US2022/082139 patent/WO2023122665A1/en not_active Ceased
- 2022-12-21 KR KR1020247021095A patent/KR20240121771A/ko active Pending
- 2022-12-22 TW TW111149551A patent/TW202330034A/zh unknown
-
2024
- 2024-06-20 US US18/749,129 patent/US20240408009A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202330034A (zh) | 2023-08-01 |
| AU2022417501A1 (en) | 2024-07-04 |
| CA3242136A1 (en) | 2023-06-29 |
| IL313658A (en) | 2024-08-01 |
| JP2025500483A (ja) | 2025-01-09 |
| EP4452320A1 (en) | 2024-10-30 |
| WO2023122665A1 (en) | 2023-06-29 |
| US20240408009A1 (en) | 2024-12-12 |
| KR20240121771A (ko) | 2024-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2708374C2 (ru) | Комбинированная терапия для лечения рака | |
| MX2021013943A (es) | Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1. | |
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| MX385543B (es) | Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b. | |
| MY206825A (en) | Pyridazinyl thiazolecarboxamide compound | |
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| EA201690738A1 (ru) | Ингалятор сухого порошка | |
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| RU2018103064A (ru) | Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| RU2008141433A (ru) | Терапия опухолей с использованием сосудистого эндотелиального фактора роста и антитела к рецептору типа 2 человеческого эпителиального фактора роста | |
| MX2024007749A (es) | Formulaciones clinicas de anticuerpos anti-tigit. | |
| JP2020117553A5 (https=) | ||
| Michallet et al. | Recent developments in the treatment of aggressive non-Hodgkin lymphoma | |
| JOP20200014A1 (ar) | توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf | |
| MX2021004120A (es) | Regimen de dosificacion para antagonistas de tfpi. | |
| NZ740351A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
| JOP20230243A1 (ar) | طرق لعلاج السرطان بواسطة إعطاء أجسام مضادة موجّهة ضد pd1 تحت الجلد | |
| WO2020081579A8 (en) | Monoclonal antibodies against human dickkopf3 and uses thereof | |
| JOP20250015A1 (ar) | تركيبة صيدلانية للأجسام المضادة ضد cd20 واستخداماتها | |
| MX2018005876A (es) | Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas. | |
| JP2018522881A5 (https=) | ||
| WO2024206868A3 (en) | Methods of treating tumors with anti-tigit antibodies | |
| Koya et al. | Fludarabine may overcome resistance to rituximab in IgM-related neuropathy |